Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
12.75 (USD) • At close December 27, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Corbus Pharmaceuticals Holdings, Inc. |
Symbool | CRBP |
Munteenheid | USD |
Prijs | 12.75 |
Beurswaarde | 155,288,625 |
Dividendpercentage | 0% |
52-weken bereik | 5.665 - 61.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Yuval Cohen Ph.D. |
Website | https://www.corbuspharma.com |
An error occurred while fetching data.
Over Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)